The firm is shifting its resources to fund and expand its Phase I clinical trial of givastomig in CLDN18.2-expressing advanced solid tumor patients.

The FDA approved subcutaneous nivolumab for solid tumors, tiselizumab for advanced gastric and GEJ cancers, and key 2024 breast cancer breakthroughs are reviewed. Experts provide perspective on ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women's Hospital, is the corresponding author of a paper published in the ...

Halozyme provides subcutaneous drug delivery solutions, with several major new products recently approved. Click here to find ...

The U.S. Food and Drug Administration has approved Opdivo Qvantig (nivolumab and hyaluronidase-nvhy) injection for ...

Monoclonal Antibodies IndustryThe global monoclonal antibodies (mAbs) industry, valued at USD 186 billion in 2021, is ...

CARsgen Therapeutics' claudin 18.2-targeting autologous CAR-T therapy satricabtagene autoleucel (satri-cel) has shown efficacy in gastric cancer, in a rare win for this type of cell therapy in a solid ...

Raymond Y. Huang, MD, Ph.D., of the Department of Radiology at Brigham and Women’s Hospital, is the corresponding author of a paper published in the Journal of Clinical Oncology, “Comparative Analysis ...

Roche Holding AG kicked off the new year (again) with a potential $1 billion deal, including $80 million up front, for exclusive rights to Innovent Biologics Inc.’s IBI-3009, a DLL3-targeting antibody ...

FDA approves the first subcutaneous version of nivolumab, making PD-1 inhibitors available to new groups of patients.

The approval of Opdivo Qvantig was supported by data from the randomized, open-label phase 3 CheckMate-67T study.

Almost exactly 10 years after the FDA’s initial FDA approval for Bristol Myers Squibb’s Opdivo as the first PD-1 inhibitor in ...